GB201912318D0 - Improvements in drug delivery - Google Patents

Improvements in drug delivery

Info

Publication number
GB201912318D0
GB201912318D0 GBGB1912318.1A GB201912318A GB201912318D0 GB 201912318 D0 GB201912318 D0 GB 201912318D0 GB 201912318 A GB201912318 A GB 201912318A GB 201912318 D0 GB201912318 D0 GB 201912318D0
Authority
GB
United Kingdom
Prior art keywords
drug delivery
drug
delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GBGB1912318.1A
Other versions
GB2574525A (en
GB2574525B (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sutura Therapeutics Ltd
Original Assignee
Sutura Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sutura Therapeutics Ltd filed Critical Sutura Therapeutics Ltd
Priority to GB1912318.1A priority Critical patent/GB2574525B/en
Priority claimed from GB1522548.5A external-priority patent/GB2545898B/en
Publication of GB201912318D0 publication Critical patent/GB201912318D0/en
Publication of GB2574525A publication Critical patent/GB2574525A/en
Application granted granted Critical
Publication of GB2574525B publication Critical patent/GB2574525B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02Linear peptides containing at least one abnormal peptide link
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GB1912318.1A 2015-12-21 2015-12-21 Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides Active GB2574525B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB1912318.1A GB2574525B (en) 2015-12-21 2015-12-21 Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1912318.1A GB2574525B (en) 2015-12-21 2015-12-21 Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides
GB1522548.5A GB2545898B (en) 2015-12-21 2015-12-21 Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides

Publications (3)

Publication Number Publication Date
GB201912318D0 true GB201912318D0 (en) 2019-10-09
GB2574525A GB2574525A (en) 2019-12-11
GB2574525B GB2574525B (en) 2020-09-02

Family

ID=68109014

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1912318.1A Active GB2574525B (en) 2015-12-21 2015-12-21 Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides

Country Status (1)

Country Link
GB (1) GB2574525B (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0972779A3 (en) * 1987-10-28 2004-10-20 Howard Florey Institute Of Experimental Physiology And Medicine Oligonucleotide-polyamide conjugates
AU2008317566B2 (en) * 2007-10-26 2014-05-01 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
ES2593836T3 (en) * 2009-04-24 2016-12-13 Biomarin Technologies B.V. Oligonucleotide comprising an inosine to treat DMD
KR20130103662A (en) * 2010-04-19 2013-09-24 엔라이프 떼라퓨틱스, 에스.엘. Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types
WO2013150338A1 (en) * 2012-04-04 2013-10-10 Centre National De La Recherche Scientifique Stapled cell penetrating peptides for intracellular delivery of molecules
EP2911697A1 (en) * 2012-10-26 2015-09-02 Nlife Therapeutics S.L. Compositions and methods for selective delivery of oligonucleotide molecules to cell types

Also Published As

Publication number Publication date
GB2574525A (en) 2019-12-11
GB2574525B (en) 2020-09-02

Similar Documents

Publication Publication Date Title
HK1247878A1 (en) Drug delivery device
HK1247875A1 (en) Drug delivery device
HK1248626A1 (en) Drug delivery device
IL259530A (en) Shape changing drug delivery devices and methods
IL249777A0 (en) Drug delivery device
HK1246707A1 (en) Drug delivery device
IL250813A0 (en) Drug delivery device
HUE056904T2 (en) Drug delivery device
GB201522548D0 (en) Improvements in drug delivery
HK1258970A1 (en) Medical delivery device
GB201506788D0 (en) Medicament delivery device
HK1244733A1 (en) Drug delivery device
GB201515650D0 (en) Medicament delivery devices
GB2563875B (en) Improvements in drug delivery
HUE052701T2 (en) Drug delivery devices
HUE057487T2 (en) Drug delivery system
SG10201502463TA (en) A drug delivery composition
IL249789A0 (en) Drug delivery device
IL246874A0 (en) Drug delivery system
GB2537639B (en) Medicament delivery device
GB201607778D0 (en) Drug delivery device
HK1247871A1 (en) Drug delivery device
HK1247870A1 (en) Drug delivery device
GB201410507D0 (en) Drug delivery enhancement agents
GB2580569B (en) Improvements in drug delivery